MyFinsight
Home
Blog
About
Contact
Download
Download image
Maturities of marketable
securities
$22,408,285
Proceeds from line of
credit
$2,750,000
Sales of marketable
securities
$305,000
Exercise of warrants
$265,655
Net cash provided by
(used in) investing...
$14,426,645
Net cash provided by
financing activities
$265,655
Effect of exchange rate
changes on cash
$173,634
Canceled cashflow
$8,286,640
Canceled cashflow
$2,750,000
Net increase in cash
and cash...
$4,904,758
Canceled cashflow
$9,961,176
Purchases of marketable
securities
$8,175,851
Purchases of property and
equipment
$110,789
Impairment of in-process
r&d
$4,624,000
Deferred collaboration
revenue
$1,250,000
Accounts payable
$1,124,928
Stock-based compensation
$900,236
Prepaid expenses and
other current assets
-$419,736
Reduction of right-of-use
assets
$186,277
Change in accrued
interest on marketable...
$164,534
Depreciation and
amortization
$24,801
Repayments of line of credit
$2,750,000
Net cash (used in)
provided by operating...
-$9,961,176
Canceled cashflow
$8,694,512
Collaboration credits-KIO301
$7,066,237
Income tax (benefit)
expense
-$1,282,149
Change in fair value of
contingent consideration
-$1,252,174
Interest income
$894,002
Net (loss) income
-$10,835,154
Canceled cashflow
$10,494,562
Accrued expenses
-$2,337,649
Tax and other
receivables
$1,493,270
Change in fair value of
contingent consideration
-$1,252,174
Accrued collaboration
credit
-$1,174,518
Collaboration receivables
$921,573
Deferred taxes
-$388,538
Accretion of discount on
marketable securities
$112,305
Operating lease
liabilities
-$103,845
Other assets
$34,172
Net realized gain on
marketable securities
$2,371
Change in unrealized
gain on cash...
-$119
Collaboration
credits-Research And Development...
$587,447
Research and development
$10,780,397
General and
administrative
$5,745,087
Canceled cashflow
$587,447
In-process r&d impairment
$4,624,000
Other segment
expenses
$180,232
KIO301
$7,217,067
Unallocated Research And
Development
$3,414,684
KIO104
$718,552
KIO101
$17,541
Back
Back
Cash Flow
source: myfinsight.com
KIORA PHARMACEUTICALS INC (KPRX)
KIORA PHARMACEUTICALS INC (KPRX)